Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957381 | 0.94 | MEN1 (0.40) | SMN1; SMN2MEN1CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL8627165 | 0.92 | MEN1 (0.39) | SMN1; SMN2MEN1CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL8625168 | 0.89 | MLYCD (0.40) | SMN1; SMN2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6296583 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5966898 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5966823 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1822076 | 0.85 | MLYCD (0.44) | SMN1; SMN2MEN1KMT2ASLC7A5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11694104 | 0.84 | MLYCD (0.43) | SMN1; SMN2MEN1KMT2ASLC7A5ALDH1A1 | |
| SCHEMBL1562840 | 0.82 | ACE (0.41) | ALDH1A1GLATSHRMLYCD | |
| SCHEMBL27459998 | 0.82 | ACE (0.41) | ALDH1A1GLATSHRMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0918059-B1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-06-25 | — | — | EP | disclosed |
| US-6521654-B2 | For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| EP-0918059-A1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | SMN1; SMN2 3303/4885MEN1 4417/4885CYP3A4 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.